| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/22/2003 | EP0728009B1 Use of an agent which modulates tyrosine phosphorylation for modulating the permeability of a psychological barrier |
| 01/22/2003 | EP0646115B1 Heterocyclic-cyclic amine derivatives |
| 01/22/2003 | CN1392874A Cyclic amidine compounds |
| 01/22/2003 | CN1391942A New medicine for anti-cancer, anti-AIDs and giving-up drug habits and its preparing and applying method |
| 01/22/2003 | CN1391935A Fast acting sobering-up and liver protecting medicine |
| 01/22/2003 | CN1099425C 新的肽衍生物 New peptide derivatives |
| 01/22/2003 | CN1099419C Azebicyclic compound |
| 01/22/2003 | CN1099413C Certain fused N-pyrrolylaniline: new class of GABA brain receptor ligand |
| 01/22/2003 | CN1099286C Use of forskolin in manufacture of medicament for treatment of alcohol addiction |
| 01/22/2003 | CN1099285C Novel anti-spasmodic and anti-inflammatory agent composition and its process for manufacturing |
| 01/21/2003 | US6509515 Transgenic mice expressing mutant human APP and forming congo red staining plaques |
| 01/21/2003 | US6509499 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment |
| 01/21/2003 | US6509483 Method for the preparation of citalopram |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |
| 01/21/2003 | US6509365 Useful as inhibitors of poly(ADP-ribose)polymerase and for the production of drugs. |
| 01/21/2003 | US6509363 P38 is a mitogen-activated protein kinase; pyrrole, oxazole, thiazole, and imidazole derivatives |
| 01/21/2003 | US6509357 1-aryl or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 01/21/2003 | US6509351 A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation |
| 01/21/2003 | US6509346 Chemokine receptor antagonists and methods of use therefor |
| 01/21/2003 | US6509340 Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT1B/1D ligands |
| 01/21/2003 | US6509333 1-(3-methyl-1-(1,3-dihydro-1-methyl-2-oxo-5-phenyl-2H-1,4 -benzodiazepin-3-ylcarbamoyl)-butyl)-cyclopent-3-enecarboxylic amide, for example; gamma-secretase inhibitors; Alzhemier's disease, Down's Syndrome |
| 01/21/2003 | US6509328 Glutamate receptor antagonists |
| 01/21/2003 | US6509029 Mixtures; food, cosmetics, drugs |
| 01/21/2003 | US6509028 Methods and compositions for treating pain of the mucous membrane |
| 01/21/2003 | US6509015 Human antibodies that bind human TNFa |
| 01/21/2003 | US6509005 Nonozone depleting stable aerosol; treating nausea and vomiting associated with chemotherapy; muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, epilepsy, glaucoma, bronchial asthma and mood disorders |
| 01/21/2003 | US6508585 Differential scanning calorimeter |
| 01/21/2003 | CA2123704C Methods and compositions utilizing pure s(+)isomer fluoxetine |
| 01/21/2003 | CA2078106C Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
| 01/21/2003 | CA1341418C Substantially-pure non-inflammatory hyaluronic acid |
| 01/18/2003 | CA2352702A1 Novel human proton gated ion channel |
| 01/17/2003 | WO2002006269A1 Cyclic amino acid derivatives |
| 01/17/2003 | CA2415964A1 Cyclic amino acid derivatives |
| 01/16/2003 | WO2003005038A1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 01/16/2003 | WO2003005036A2 Epf receptor assays, compounds and therapeutic compositions |
| 01/16/2003 | WO2003004661A2 Adenovital vectors with cell type specificity for mesenchymal cells |
| 01/16/2003 | WO2003004615A2 Secreted proteins |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004604A2 Phage displayed pdz domain ligands |
| 01/16/2003 | WO2003004527A2 Novel neurotrophic factors |
| 01/16/2003 | WO2003004526A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines |
| 01/16/2003 | WO2003004511A2 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 01/16/2003 | WO2003004503A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | WO2003004501A2 (hetero) aryl substituted benzofurans as 5-ht ligands |
| 01/16/2003 | WO2003004498A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 01/16/2003 | WO2003004495A1 Novel immunomodulating compounds |
| 01/16/2003 | WO2003004494A1 Pyridazinone compound as adenosine antagonists |
| 01/16/2003 | WO2003004493A1 Novel compounds, their preparation and use |
| 01/16/2003 | WO2003004492A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | WO2003004488A1 Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors |
| 01/16/2003 | WO2003004487A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | WO2003004485A1 Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof |
| 01/16/2003 | WO2003004480A2 Substituted piperazine and diazepanes as histamine h3 receptor agonists |
| 01/16/2003 | WO2003004478A1 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea and its use in the treatment of conditions associated with glycogen-synthase kinase-3(gsk3) |
| 01/16/2003 | WO2003004475A1 Heterocyclic amines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004472A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | WO2003004470A1 Crystalline forms of 'r-(r*,r*)!-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 01/16/2003 | WO2003004468A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 01/16/2003 | WO2003004467A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | WO2003004453A1 Compounds used to treat alcoholism |
| 01/16/2003 | WO2003004452A1 Substituted 1-aryl-but-3-enylamine and 1-ary-but-2-enylamine compounds |
| 01/16/2003 | WO2003004049A2 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 01/16/2003 | WO2003004046A2 Use of xaa-pro peptidases for the treatment of substance p-related disorders |
| 01/16/2003 | WO2003004034A1 Method for inducing analgesia comprising administration alternatively of an opioid receptor agonist and an opioid receptor like receptor 1 agonist for and an implantable infusion pump |
| 01/16/2003 | WO2003004033A1 Sustained release formulations of oxymorphone |
| 01/16/2003 | WO2003004032A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | WO2003004031A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | WO2003004030A1 Oxymorphone controlled release formulations |
| 01/16/2003 | WO2003004029A1 Methods of making sustained release formulations of oxymorphone related applications |
| 01/16/2003 | WO2003004027A1 Substituted anilinic piperidines as mch selective antagonists |
| 01/16/2003 | WO2003004024A1 Injectable sustained-release microspheres of huperzine a compounds |
| 01/16/2003 | WO2003004023A1 1-alkyl-2-aryl-benzimidazole derivatives, their use for producing medicaments and pharmaceutical preparations containing said derivatives |
| 01/16/2003 | WO2003004018A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives as gaba-a receptor ligands |
| 01/16/2003 | WO2003004017A1 Synergistic compositions of n-acylhomoserine lactones and 4-quinolones |
| 01/16/2003 | WO2003004016A1 Use of substituted gamma-lactone compounds as medicaments |
| 01/16/2003 | WO2003004015A1 Oil-in-water emulsions comprising a benzodiazepine drug |
| 01/16/2003 | WO2003004000A2 Topical composition for treating pain |
| 01/16/2003 | WO2003003824A1 Potential-dependent ca2+ channel a1b knockout non-human animal |
| 01/16/2003 | WO2002096415A3 Use of azetidinone substituted derivatives in the treatment of alzheimer's disease |
| 01/16/2003 | WO2002062327A3 Method of treating neurological disorders using acetone derivatives |
| 01/16/2003 | WO2002051837A3 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| 01/16/2003 | WO2002051389A3 Aerogel powder comprising therapeutic agents |
| 01/16/2003 | WO2002050062A3 Benzimidazole and pyridylimidazole derivatives as ligands for gaba receptors |
| 01/16/2003 | WO2002045658A3 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof |
| 01/16/2003 | WO2002040016A3 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 01/16/2003 | WO2002038177A3 Adjuvant combination formulations |
| 01/16/2003 | WO2002036107A3 Treatment of motor fluctuations with 5-hydroxytryptamine 1a receptor activity enhancing coumpounds |
| 01/16/2003 | WO2002031109A3 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 01/16/2003 | WO2002026216A8 Pharmaceutical oxan preparation |
| 01/16/2003 | WO2002021141A3 Methods and compositions for diseases associated with amyloidosis |
| 01/16/2003 | WO2002020047A3 Chlamydial peptides and their mimics in demyelinating disease |
| 01/16/2003 | WO2002016587A3 Microtubule-associated proteins and tubulins |
| 01/16/2003 | WO2002012196A3 Lactam compounds and their use as inhibitors of serine proteases and method |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | WO2002007774A3 Methods for therapy of neurodegenerative disease of the brain |
| 01/16/2003 | WO2002000209A3 Gabapentin analogues for sleep disorders |
| 01/16/2003 | WO2001098323A8 G-protein coupled receptors |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | WO2001068880A9 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 01/16/2003 | WO2001062705A3 Aminoalcohol derivatives |